Ghione et al. [110] conducted a multicenter retrospective cohort study and analyzed the outcomes of patients with PTCL (AITL, TFH-PTCL, and PTCL-NOS) treated with HDAC inhibitor, either in combination (duvelisib, carfilzomib, or lenalidomide) or as single agents. The gene discussed is HDAC9; the disease is angioimmunoblastic T-cell lymphoma.